On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
TuesdayApr 18, 2017 1:05 pm

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Reiterated with ‘Buy’ Rating, $14 PT at Aegis Capital

Trevena, Inc. (NASDAQ: TRVN) has been reiterated with a ‘Buy’ rating and $14 price target at Aegis Capital Corp., which noted that the commercial potential of the company’s Olinvo is “under-appreciated.” Olinvo differs from existing active drugs indicated for post-operative pain management by its mechanism of action, and it could be the first in a new class of molecules to receive FDA approval. The Aegis analyst noted that phase 3 read-outs demonstrated efficacy near the equivalent of morphine, as well as with improved side effect profiles, especially for respiratory depression and GI side effects. Aegis also estimated that Olinvo could generate…

Continue Reading

TuesdayApr 18, 2017 12:21 pm

NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Expands IP with Japanese Patent for Target Selector™ Liquid Biopsy Platform

Biocept (NASDAQ: BIOC) this morning said it has been awarded a Japanese patent covering the use of antibodies for the capture of any target of interest from any sample type on a device surface including circulating tumor cells (CTCs). The patent, entitled “Devices And Methods Of Cell Capture And Analysis,” is broader than previously issued patents owned by the company and is the 19th patent issued to Biocept related to its core liquid biopsy technology. "This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. Expanding our intellectual…

Continue Reading

TuesdayApr 18, 2017 12:18 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG): UnitedHealthcare Agrees to Cover ThyraMIR®; Shares Skyrocket

Interpace Diagnostics Group (NASDAQ: IDXG) shares are up 95% in late morning trade after the company said that UnitedHealthcare, the largest health plan in the United States, has agreed to cover its ThyraMIR® test used in assessing indeterminate thyroid nodule fine needle aspirate (FNA) biopsies. The coverage is now in effect and is subject to members' specific benefit plan design. Including the new coverage with UnitedHealthcare, Interpace's ThyGenX® and ThyraMIR assays are now covered for approximately 250 million patients nationwide. To view the full press release, visit: http://nnw.fm/CFDp7 About Interpace Diagnostics Group, Inc. Interpace is a fully integrated commercial company…

Continue Reading

TuesdayApr 18, 2017 8:15 am

NetworkNewsBreaks – Neurotrope, Inc. (NASDAQ: NTRP) Receives ‘Buy’ Rating, $31 PT at Aegis Capital

Aegis Capital Corp. recently issued a ‘Buy’ rating and price target of $31 on shares of Neurotrope, Inc. (NASDAQ: NTRP). The company has completed enrollment of its phase 2b clinical trial of Bryostatin-1 for the treatment of Alzheimer’s disease. The analyst noted that the company will be driven by the data from this trial, which is expected in late April. Based on expected sales of drugs that are intended to slow the decline in cognitive function or reduce symptoms, which have achieved market valuations in the $1 billion range after positive phase 2 data in the past, the analyst believes…

Continue Reading

MondayApr 17, 2017 2:48 pm

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Expands eXp Realty Management Team

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, today announced the addition of four industry veterans to the management team of eXp Realty. The newly-appointed additions include Kee Wah Chung as Vice President of Agent Experience; Kathy Gordon as Vice President, Brokerage Operations; Scott Petronis as Chief Product and Technology Officer; and Mitch Robinson as Senior Vice President, Marketing and Communications. “Our daily objective is to be the most agent-centric brokerage firm in the world,” Russ Cofano, president and general counsel of eXp World Holdings, stated in the news release. “Adding Kee Wah, Kathy, Scott…

Continue Reading

MondayApr 17, 2017 1:01 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 17, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CBLI 76.92% – News: Commences in vivo biocomparability study; EMA accepts pediatric investigation plan GLGI 52.27% – News: Posts financial results for periods ended February 28, 2017 MTBC 15.46% – News: Posts unaudited financial results for the period ended March 31, 2017 IDND 12.50% – News: Commences milk project with Naarmann in Pakistan BPTH 11.24% – News: Names VP of clinical research OWCP 9.04% – News: Presenting at Monaco Growth Forums April 25-26 RPRX…

Continue Reading

MondayApr 17, 2017 11:55 am

NetworkNewsBreaks – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) Fails To Meet Endpoints in Phase 2 Trial of Tarextumab; Discontinues Enrollment in Brontictuzumab Trial

OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) shares are down 19% after the company reported top-line results from the phase 2 PINNACLE clinical trial of tarextumab in previously untreated patients with extensive-stage small cell lung cancer. The combination of tarextumab plus chemotherapy results were undifferentiated from those of chemotherapy plus placebo, which means the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation. Additionally, the company said it is discontinuing enrollment in the phase 1b clinical trial of brontictuzumab in combination with trifluridine/tipiracil in third-line colorectal cancer…

Continue Reading

MondayApr 17, 2017 11:38 am

NetworkNewsBreaks – Westport Fuel Systems (NASDAQ: WPRT) Signs Definitive Agreement to Sell its APU Assets for $70M; Shares Rally

Westport Fuel Systems (NASDAQ: WPRT) shares jumped 16% this morning after the company said it has entered into a definitive agreement to sell the assets of its Auxiliary Power Unit (APU) business for $70 million. The sale is consistent with the company’s strategy to streamline its business and focus on alternative fuel solutions for the transportation and automotive industries. The transaction is expected to close within a few weeks. "After a careful assessment of the APU product line and its fit with the other Westport Fuel Systems businesses, we decided it made the most sense for our shareholders to pursue…

Continue Reading

MondayApr 17, 2017 9:44 am

NetworkNewsBreaks – CytoDyn’s (CYDY) PRO 140 Not Granted Orphan Drug Designation Due to Broad HIV Treatment Potential

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that its application for Orphan Drug Designation for PRO 140 was not granted by the Office of Orphan Products Development of the U.S. Food and Drug Administration. Per the update, the company’s clinical stage monoclonal antibody was deemed to have potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested. CytoDyn is currently conducting multiple Phase 2b/3 trials of PRO 140, including one in combination with other antiretroviral agents in the patient population outlined in the company’s Orphan Drug Designation application, as…

Continue Reading

ThursdayApr 13, 2017 1:59 pm

NetworkNewsBreaks – Function(x), Inc. (NASDAQ: FNCX) Receives $3.20 PT from SeeThruEquity

SeeThruEquity has initiated coverage and issued a price target of $3.20 on shares of Function(x), Inc. (NASDAQ: FNCX). The analyst noted that the company’s media properties, Wetpaint and Rant, had approximately 210 million page views in March and have over 10 million social media followers. The analyst also cited the company’s steps to restructure its balance sheet, demonstrated by the $4.8 million new equity capital raised in February. Function(x) is also evaluating the sale of non-core assets and is in the process of renegotiating its debt. For more information, visit www.functionxinc.com About Function(x), Inc. Function(x) operates Wetpaint.com and Rant. Wetpaint…

Continue Reading

Contact us: 212.418.1217